ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2028

The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

Martha S. van Ginkel1, Andor WJM Glaudemans1, Bert van der Vegt1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

Meeting: ACR Convergence 2022

Keywords: Imaging, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Primary Sjögren’s syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT) type and most commonly arise within the parotid glands. Although fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) is widely used in oncology and inflammatory diseases, the usefulness of FDG-PET/CT in detecting pSS-associated lymphomas is not yet clear. Therefore, we aimed to assess the usefulness of FDG-PET/CT for the diagnosis of pSS associated lymphomas in a large retrospective cohort of pSS patients.

Methods: PSS patients fulfilling the ACR-EULAR criteria for pSS, who underwent FDG-PET/CT between 2010 and 2021, were recruited from the electronic patient file system of the University Medical Center Groningen. Patients were excluded if FDG-PET/CT was performed due to an intercurrent malignancy not related to pSS. All FDG-PET/CT scans were performed on integrated PET/CT camera systems (Siemens Biograph mCT or Vision) and were reconstructed according to standardized European guidelines. FDG-PET/CT scans were visually and semi-quantitatively analysed by two investigators, focusing on the uptake in salivary and lacrimal glands and lymph nodes. Furthermore, systemic disease activity was assessed in the organs that can be visualized by FDG-PET/CT.

Results: Of the 71 included pSS patients, 26 (37%) were histologically diagnosed with a lymphoma. 23 (88%) of the pSS-associated lymphomas were of the MALT type; biopsy location: parotid (N=17), lacrimal gland (N=2), lungs (N=2) and lymph node (N=2). The maximum standardized uptake value (SUVmax) and the SUVpeak were significantly higher in both the parotid and the submandibular glands of pSS patients with lymphoma (p< 0.001 for both parameters in both glands). Furthermore, patients with lymphoma more often showed presence of nodular lung lesions, compared to non-lymphoma patients (31% vs 7%, p=0.014). There was no significant difference in the presence of abnormal FDG-uptake in lymph nodes (81% for lymphoma vs 70% for non-lymphoma). Furthermore, no differences were found in the presence of arthritis, myositis, enthesopathy, vasculitis, nephritis or interstitial lung disease, and lymphoma patients did not more frequently show abnormal uptake in the thyroid gland, liver, spleen or pancreas, compared to non-lymphoma patients.

Conclusion: PSS patients with lymphoma have significantly higher SUV-values in both the parotid and submandibular glands, and more often show nodular lung lesions. Standardized FDG-PET/CT can be useful in the diagnostic work-up of pSS-associated lymphomas, since (1) it can assist in the decision if, and subsequently at which location, a biopsy is needed, and (2) it could reduce the number of biopsies in patients who do not have salivary gland FDG-PET/CT abnormalities nor presence of nodular lung lesions. Importantly, abnormal uptake in lymph node regions is frequent in pSS and does not discriminate between lymphoma and non-lymphoma.


Disclosures: M. van Ginkel, None; A. Glaudemans, None; B. van der Vegt, None; A. Vissink, None; F. Kroese, None; H. Bootsma, Novartis, Bristol-Myers Squibb(BMS).

To cite this abstract in AMA style:

van Ginkel M, Glaudemans A, van der Vegt B, Vissink A, Kroese F, Bootsma H. The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-value-of-fdg-pet-ct-in-the-detection-of-lymphomas-associated-with-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-value-of-fdg-pet-ct-in-the-detection-of-lymphomas-associated-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology